CSTONE PHARMA-B News

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE PRESENTS PRECLINICAL DATA ON CS2009 AT THE 2024 SITC ANNUAL MEETING

Nov 11 12:00

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE TO PRESENT LATEST CLINICAL DATA ON CS5001 FOR LYMPHOMA AT THE 66TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING

Nov 6 08:00

CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2024

Nov 5 19:21

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES MHRA APPROVAL OF SUGEMALIMAB FOR FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE UK

Oct 31 12:00

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES PUBLICATION OF POPULATION PHARMACOKINETICS MODELLING OF CEJEMLY (SUGEMALIMAB) IN BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Oct 28 12:00

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES PATENT PUBLICATION FOR FIRST-IN-CLASS ANTIBODY-DRUG CONJUGATE (ADC) CS5006

Oct 21 08:00

CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 SEPTEMBER 2024

Oct 7 17:33

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE TO PRESENT PRECLINICAL DATA ON CS2009 AT THE 2024 ANNUAL MEETING OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC)

Oct 7 08:00

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE'S STRATEGIC PARTNER HENGRUI INITIATES A PHASE III CLINICAL TRIAL OF ANTI-CTLA-4-BASED COMBINATION THERAPY AS FIRST-LINE TREATMENT FOR ADVANCED HEPATOCELLULAR CARCINOMA

Oct 2 12:00

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES LONG-TERM SURVIVAL DATA FOR CEJEMLY (SUGEMALIMAB) IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT OF STAGE IV NSCLC AT ESMO 2024

Sep 16 12:00

CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 2024

Sep 5 16:32

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT -CSTONE ANNOUNCES APPROVAL OF MANUFACTURING LOCALIZATION REGISTRATION APPLICATION FOR AYVAKIT(AVAPRITINIB TABLETS, 100 MG) BY CHINA NMPA

Aug 15 08:00

CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2024

Aug 6 16:34

CSTONE PHARMA-B: INSIDE INFORMATION ANNOUNCEMENT - CSTONE ANNOUNCES EUROPEAN COMMISSION APPROVAL OF SUGEMALIMAB (CEJEMLY) AS FIRST-LINE TREATMENT FOR NON-SMALL CELL LUNG CANCER

Jul 26 17:00

CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2024

Jul 5 16:42

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE AND HENGRUI ENTER INTO AN EXCLUSIVE PROMOTION AGREEMENT OF AYVAKIT (AVAPRITINIB TABLETS) IN MAINLAND CHINA

Jul 3 17:00

CSTONE PHARMA-B: CHANGE OF JOINT COMPANY SECRETARY, PROCESS AGENT AND AUTHORIZED REPRESENTATIVE AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Jun 18 22:32

CSTONE PHARMA-B: SIXTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION

Jun 18 21:50

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES APPROVAL OF MANUFACTURING LOCALIZATION REGISTRATION APPLICATION FOR AYVAKIT (AVAPRITINIB TABLETS) BY CHINA NMPA

Jun 13 12:00

CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2024

Jun 6 18:07